Effects of Sevelamer Carbonate Versus Calcium Acetate on Vascular Calcification, Inflammation, and Endothelial Dysfunction in Chronic Kidney Disease

Overview

Journal Clin Transl Sci

Specialties Biomedical Engineering
General Medicine

Date 2021 Oct 2

PMID 34599865

Citations 11

Authors

Darius L Mason

Kavitha Godugu

Daryl Nnani

Shaker A Mousa

Affiliations

Soon will be listed here.

Abstract

Hyperphosphatemia is present in most patients with end-stage renal disease (ESRD) and has been associated with increased cardiovascular mortality. Phosphate binders (calcium-based and calcium free) are the mainstay pharmacologic treatment to lower phosphorus levels in patients with ESRD. We evaluated biochemical markers of vascular calcification, inflammation, and endothelial dysfunction in patients with chronic kidney disease (CKD) treated with sevelamer carbonate (SC) versus calcium acetate (CA). Fifty patients with CKD (stages 3 and 4) were enrolled and assigned to treatment with SC and CA for 12 weeks. At the end of the study the biomarkers of vascular calcification, inflammation, and endothelial dysfunction were analyzed. A significant increase in HDL-cholesterol was observed with SC but not with CA in patients with CKD. Treatment with SC reduced serum phosphate, calcium phosphate, and FGF-23 levels and there was no change with CA treatment. The inflammatory markers IL-8, IFN-γ, and TNFα decreased with response to both treatments. The levels of IL-6 significantly increased with CA treatment and no change was observed in the SC treatment group. SC showed favorable effects on anti-inflammatory and vascular calcification biomarkers compared to CA treatment in patients with CKD stages 3 and 4 with normal phosphorous values.

Citing Articles

Therapeutic effectiveness and safety profile of lanthanum carbonate in conjunction with calcium carbonate for managing hyperphosphatemia in hemodialysis patients: a meta-analysis of randomized controlled trials.

Fang H, Chen C Am J Transl Res. 2024; 16(11):6980-6990.

PMID: 39678559 PMC: 11645603. DOI: 10.62347/WXBL2590.

Phosphorous metabolism and manipulation in chronic kidney disease.

Marando M, Tamburello A, Salera D, Di Lullo L, Bellasi A Nephrology (Carlton). 2024; 29(12):791-800.

PMID: 39433296 PMC: 11579558. DOI: 10.1111/nep.14407.

Effects of the novel sodium-dependent phosphate cotransporter 2b inhibitor DZ1462 on hyperphosphatemia in chronic kidney disease.

Lu X, Yu L, Guo Q, Zhang L, Jiang S Am J Transl Res. 2024; 16(3):768-780.

PMID: 38586086 PMC: 10994808. DOI: 10.62347/UGTW5471.

Phosphate in Cardiovascular Disease: From New Insights Into Molecular Mechanisms to Clinical Implications.

Turner M, Beck L, Hill Gallant K, Chen Y, Moe O, Kuro-O M Arterioscler Thromb Vasc Biol. 2024; 44(3):584-602.

PMID: 38205639 PMC: 10922848. DOI: 10.1161/ATVBAHA.123.319198.

Causal effects of systemic inflammatory regulators on chronic kidney diseases and renal function: a bidirectional Mendelian randomization study.

Li H, Li M, Liu C, He P, Dong A, Dong S Front Immunol. 2023; 14:1229636.

PMID: 37711613 PMC: 10498994. DOI: 10.3389/fimmu.2023.1229636.

References

Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri A, Koukoudis P . Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant. 2002; 17(3):435-41. DOI: 10.1093/ndt/17.3.435. View

Jean G, Terrat J, Vanel T, Hurot J, Lorriaux C, Mayor B . High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009; 24(9):2792-6. DOI: 10.1093/ndt/gfp191. View

Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T . Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int. 2006; 69(3):531-7. DOI: 10.1038/sj.ki.5000020. View

Hutchison A . Oral phosphate binders. Kidney Int. 2009; 75(9):906-14. DOI: 10.1038/ki.2009.60. View

Moe S, Reslerova M, Ketteler M, ONeill K, Duan D, Koczman J . Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005; 67(6):2295-304. DOI: 10.1111/j.1523-1755.2005.00333.x. View

Viegas C, Araujo N, Marreiros C, Simes D . The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts. Aging (Albany NY). 2019; 11(12):4274-4299. PMC: 6628989. DOI: 10.18632/aging.102046. View

Gutierrez O, Januzzi J, Isakova T, Laliberte K, Smith K, Collerone G . Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119(19):2545-52. PMC: 2740903. DOI: 10.1161/CIRCULATIONAHA.108.844506. View

Brown R, Razzaque M . Dysregulation of phosphate metabolism and conditions associated with phosphate toxicity. Bonekey Rep. 2015; 4:705. PMC: 4455690. DOI: 10.1038/bonekey.2015.74. View

Tousoulis D, Siasos G, Maniatis K, Oikonomou E, Vlasis K, Papavassiliou A . Novel biomarkers assessing the calcium deposition in coronary artery disease. Curr Med Chem. 2012; 19(6):901-20. DOI: 10.2174/092986712799034833. View

10.

Llaurado G, Megia A, Cano A, Gimenez-Palop O, Simon I, Gonzalez-Sastre M . FGF-23/Vitamin D Axis in Type 1 Diabetes: The Potential Role of Mineral Metabolism in Arterial Stiffness. PLoS One. 2015; 10(10):e0140222. PMC: 4604080. DOI: 10.1371/journal.pone.0140222. View

11.

Locatelli F, Del Vecchio L, Violo L, Pontoriero G . Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opin Drug Saf. 2014; 13(5):551-61. DOI: 10.1517/14740338.2014.907791. View

12.

Sigrist M, Bungay P, Taal M, McIntyre C . Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant. 2005; 21(3):707-14. DOI: 10.1093/ndt/gfi236. View

13.

Ruospo M, Palmer S, Natale P, Craig J, Vecchio M, Elder G . Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018; 8:CD006023. PMC: 6513594. DOI: 10.1002/14651858.CD006023.pub3. View

14.

Muteliefu G, Enomoto A, Jiang P, Takahashi M, Niwa T . Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant. 2009; 24(7):2051-8. DOI: 10.1093/ndt/gfn757. View

15.

Affret A, Wagner S, El Fatouhi D, Dow C, Correia E, Niravong M . Validity and reproducibility of a short food frequency questionnaire among patients with chronic kidney disease. BMC Nephrol. 2017; 18(1):297. PMC: 5599889. DOI: 10.1186/s12882-017-0695-2. View

16.

Wang C, Liu X, Zhou Y, Li S, Chen Y, Wang Y . New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2015; 10(7):e0133938. PMC: 4521824. DOI: 10.1371/journal.pone.0133938. View

17.

Lee S, Lee I, Jeon J . Vascular Calcification-New Insights Into Its Mechanism. Int J Mol Sci. 2020; 21(8). PMC: 7216228. DOI: 10.3390/ijms21082685. View

18.

Fliser D, Kollerits B, Neyer U, Ankerst D, Lhotta K, Lingenhel A . Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 18(9):2600-8. DOI: 10.1681/ASN.2006080936. View

19.

Zununi Vahed S, Mostafavi S, Hosseiniyan Khatibi S, Shoja M, Ardalan M . Vascular Calcification: An Important Understanding in Nephrology. Vasc Health Risk Manag. 2020; 16:167-180. PMC: 7229867. DOI: 10.2147/VHRM.S242685. View

20.

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G . Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16(7):2205-15. DOI: 10.1681/ASN.2005010052. View